Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
HOME > COMMENTARY
COMMENTARY
- Supply of New Drugs Prior to NHI Price Listing to Increase as More Makers Target Drugs with Unmet Medical Needs
April 20, 2012
- Fewer Takers, High Pass Rate in Nat’l Pharmacists’ Exam for 1st Graduates of Six-year Education System
April 5, 2012
- Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 2
March 26, 2012
- Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 1
March 19, 2012
- Indications for Boosted Alliances, Acquisitions in Vaccine Business among Major Japanese Companies
March 13, 2012
- Further Provisions Required – One Year since the Great East Japan Earthquake
March 12, 2012
- Major US, European Drug Makers Report Growth in 2011 as Patent Cliff Approaches
March 5, 2012
- Will Wholesalers Be Able to Succeed at Reform This Time?
February 20, 2012
- Industry Should Prepare Arguments in Advance to Ward Off Possibility of 3 Consecutive NHI Price Revisions
January 23, 2012
- Will New Drug Makers Dominate Domestic Biosimilars Market?
December 26, 2011
- Pressure Mounting for Additional NHI Price Cut for Long-listed Drugs
December 12, 2011
- “Drug Discovery Support Organization” Faces Doubts: Can It Pick Winners?
November 28, 2011
- Perpetuation of Premium for New Drug Development Faces Hurdles
November 14, 2011
- Further Research Needed to Advance the Use of Regulatory Science in Regulatory Affairs
November 14, 2011
- Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
October 19, 2011
- Pinning Hope on Academia in Seeking a Radical Cure for AD
October 10, 2011
- Discussions on Amendment of PAL Now in Final Stages
October 3, 2011
- New Ideas Needed to Address “Insurance Lag” for GE Drug Makers That Submit Applications Based on Info. in Public Domain
October 3, 2011
- Korosho Revises GL for Drafting, Distributing Drug Safety Information
September 5, 2011
- Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
August 29, 2011
ページ
With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…
The workforce in the Japanese pharmaceutical sector is getting leaner and leaner, with the latest securities reports filed by 27 drug makers showing a 1.3% fall in their headcounts in FY2018, or 888 employees. The downtrend has been continuing since…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…